Nivolumab

Generic Name
Nivolumab
Brand Names
Opdivo, Opdualag
Drug Type
Biotech
Chemical Formula
-
CAS Number
946414-94-4
Unique Ingredient Identifier
31YO63LBSN
Background

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...

Indication

Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...

Associated Conditions
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
Associated Therapies
Complete Surgical Resection, Neoadjuvant Therapies
Clinical Trials
Related News

FOG-001 in Locally Advanced or Metastatic Solid Tumors

First Posted Date
2023-06-26
Last Posted Date
2024-12-17
Lead Sponsor
Parabilis Medicines, Inc.
Target Recruit Count
480
Registration Number
NCT05919264
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

First Posted Date
2023-06-15
Last Posted Date
2024-12-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
50
Registration Number
NCT05904080
Locations
🇺🇸

Methodist Jennie Edmundson Hospital, Council Bluffs, Iowa, United States

🇺🇸

Nebraska Methodist Hospital, Omaha, Nebraska, United States

🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 74 locations

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

First Posted Date
2023-06-12
Last Posted Date
2024-08-05
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT05898828
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

First Posted Date
2023-06-09
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
16
Registration Number
NCT05896839
Locations
🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

Keck Medicine of USC Koreatown, Los Angeles, California, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

and more 21 locations

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: BMS-986449
Drug: Nivolumab
First Posted Date
2023-06-05
Last Posted Date
2024-10-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
100
Registration Number
NCT05888831
Locations
🇳🇱

Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL), Amsterdam, Noord-Holland, Netherlands

🇺🇸

The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States

🇺🇸

Yale New Haven Hospital-Smilow Cancer Center, New Haven, Connecticut, United States

and more 19 locations

Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial

First Posted Date
2023-06-05
Last Posted Date
2023-06-08
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
96
Registration Number
NCT05887830

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

First Posted Date
2023-05-19
Last Posted Date
2024-12-02
Lead Sponsor
Genentech, Inc.
Target Recruit Count
102
Registration Number
NCT05867121
Locations
🇺🇸

UCLA University of California Los Angeles, Los Angeles, California, United States

🇺🇸

Yale School of Medicine, New Haven, Connecticut, United States

🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

and more 26 locations

Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer

First Posted Date
2023-05-16
Last Posted Date
2024-01-02
Lead Sponsor
Kidney Cancer Research Bureau
Target Recruit Count
23
Registration Number
NCT05859477
Locations
🇺🇸

Bureau for Cancer Research, New York, New York, United States

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

First Posted Date
2023-05-01
Last Posted Date
2024-11-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
66
Registration Number
NCT05836571
Locations
🇺🇸

University of Virginia Cancer Center, Charlottesville, Virginia, United States

🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 21 locations

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

First Posted Date
2023-04-28
Last Posted Date
2023-10-10
Lead Sponsor
Pfizer
Target Recruit Count
20605
Registration Number
NCT05834348
Locations
🇳🇴

Pfizer Norway, Oslo, Norway

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy